We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Methodology: Flow Cytometry
This four-tube assay is designed to detect virtually any hematolymphoid neoplasm in the blood or bone marrow and includes all 24 of the consensus antigens recommended for this purpose at the 2006 Bethesda Consensus Meeting on Clinical Flow Cytometry (Cytometry B Clin Cytom 72B: S14-S22, 2007). This panel includes the previously mentioned mature B cell and mature T cell tubes, and also includes two tubes targeted at myeloid blasts and maturing granulocytes and monocytes. In addition to the 15 antigens present in the B and T cell tubes, the two myeloid tubes enable evaluation of 12 additional antigens: CD11b, CD15, CD33, CD117, HLA-DR, CD71, CD36, CD64, CD13, CD14, CD123, and CD16. Potential add-on tubes include: • Myeloid 4 add-on tube • Myeloid 5 add-on tube • Cytoplasmic lineage add-on tubes • Paroxysmal nocturnal hemoglobinuria (PNH) tubes • Rule out mastocytosis tubes • B-ALL add-on tube • T-ALL add-on tube
Organ: Blood/Bone Marrow
Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)
CPT Code(s): 88184 x 1, 88185 x 26, 88189 x 1 (reference only; CPTs may vary)
Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR - • Tissue: Finely minced tissue in RPMI transport media - OR - • Body fluids: In RPMI transport media